Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis.

Autor:	Ea V; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Australia., Ngu NLY; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia., Kua HW; Department of Pathology, Monash Health, Melbourne, Australia., Mishra G; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Australia.
Jazyk:	angličtina
Zdroj:	ACG case reports journal [ACG Case Rep J] 2023 Apr 19; Vol. 10 (4), pp. e01007. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023).
DOI:	10.14309/crj.0000000000001007
Abstrakt:	Immune checkpoint inhibitors, such as pembrolizumab, are effective in the management of metastatic malignancies, such as melanoma, and are associated with a spectrum of immune-related organ toxicities, including immune-related hepatitis (ir-hepatitis). The clinical presentation of ir-hepatitis varies in onset and severity, and management involves immunosuppression with corticosteroids and mycophenolate mofetil as first and second-line agents. Several agents have been proposed as third-line options for treatment-refractory disease. We report the successful use of tacrolimus for delayed onset and treatment-refractory ir-hepatitis secondary to pembrolizumab. (© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu